On March 1, 2018, ALK alerted us to their recent decision to cease production and distribution of Pharmalgen (venom allergenic extracts) in the United States. They further stated they understand this decision will likely affect venom extract availability nationwide and are working with the FDA and Hollister-Stier (who will continue to supply venom extracts) to limit disruption. ALK also reported that they will continue to sell their remaining inventory, which they expect to last through the middle of 2018 for most species, with some lasting through the end of the year based on historical purchases.
Prior to this announcement, ALK sent a letter to practices who have purchased Pharmalgen from them since 2016.
Please refer to the AAAAI/ACAAI Joint Venom Extract Shortage Task Force Report for guidance on how to make decisions about the appropriate care for your patients currently receiving venom immunotherapy.
Can’t see the PDF preview? Access it here.